Despite the Sanz score being widely used for identifying the risk of APL, additional genetic mutations as exemplified by FLT3‐ITD or TKD, and the expression of CD34 and/or CD56 antigens are also considered to have prognostic relevance,2, 4, 11, 18, 19, 20, 21, 22, 23 whereas the explicit clinical and molecular parameters to predict relapse remains ambiguous with the first‐line use of ATRA and arsenicals. This evidence concerns the gene CD34 and acute promyelocytic leukemia.